
Traws Pharma, Inc. (NASDAQ:TRAW – Free Report) – Equities research analysts at HC Wainwright upped their FY2026 EPS estimates for Traws Pharma in a research report issued on Tuesday, November 17th. HC Wainwright analyst B. Folkes now expects that the company will post earnings per share of ($1.00) for the year, up from their previous forecast of ($1.17). HC Wainwright currently has a “Neutral” rating and a $1.00 price target on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($1.01) per share. HC Wainwright also issued estimates for Traws Pharma’s Q4 2026 earnings at ($0.12) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.51) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at $0.09 EPS.
Traws Pharma (NASDAQ:TRAW – Get Free Report) last released its quarterly earnings data on Monday, November 16th. The company reported ($0.18) EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.03.
Read Our Latest Stock Analysis on Traws Pharma
Traws Pharma Price Performance
Traws Pharma stock opened at $0.17 on Thursday. Traws Pharma has a fifty-two week low of $0.17 and a fifty-two week high of $3.23. The stock’s fifty day moving average is $0.40 and its two-hundred day moving average is $1.02.
About Traws Pharma
Traws Pharma is a clinical-stage biopharmaceutical company developing medicines for viral diseases and cancer. Its research includes antiviral candidates aimed at respiratory infections such as COVID-19 and influenza, as well as treatments for cancer. The company’s pipeline includes narazaciclib, an investigational CDK4/6 inhibitor being studied for cancer, and antiviral drug candidates designed to target SARS-CoV-2 and influenza. These products remain in development and are not established as approved treatments.
Featured Articles
- Five stocks we like better than Traws Pharma
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Traws Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Traws Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
